Solvay cuts 2026 outlook as Solvay stock falls 5.30 percent

Published on 10/20/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 2026 EBITDA was EUR 173 million versus EUR 181 million consensus. Solvay stock costs EUR 23.58 on October 20, 2026, 5.30 percent below EUR 24.90.

Quarterly pressure and cash discipline

Solvay reported EUR 173 million of underlying EBITDA for the third quarter on October 19, 2026.
The company set full-year underlying EBITDA guidance at EUR 720 million to EUR 740 million.
Solvay stock trades at EUR 23.58 at 11:16 a.m. CEST at Lang & Schwarz on October 20, 2026, 5.30 percent below the Xetra close of October 19, 2026.
Free cash flow guidance stands at EUR 120 million to EUR 150 million after EUR 90 million of transformation expenses.

Isometrische 3D-Grafik einer industriellen Produktionskette mit Fabrikgebäuden und Lagertanks — Isometrische 3D-Illustration visualisiert chemische Wertschöpfungskette, passend zu Solvay S.A. Prozessen, BE0003470755 als Referenz markiert, Illustration mit AI erstellt.

Solvay (ISIN BE0003470755) stock was trading at EUR 23.58 at Lang & Schwarz on October 20, 2026, at 11:16 a.m. CEST, down 5.30 percent versus the Xetra close of October 19, 2026, at EUR 24.90. On October 19, 2026, Solvay cut its 2026 underlying EBITDA outlook to EUR 720 million to EUR 740 million after a difficult third quarter.

Guidance now points lower

Preliminary third-quarter underlying net sales reached EUR 1.03 billion, while underlying EBITDA came to EUR 173 million and free cash flow to Solvay shareholders from continuing operations was EUR 54 million. The company attributed EUR 25 million of the quarterly EBITDA impact to the Middle East conflict, including EUR 15 million from the continued shutdown of the peroxide plant at the Sadara complex in Jubail, Saudi Arabia.

Reuters, reported by MarketScreener on October 19, 2026, said the preliminary EBITDA figure missed the EUR 181 million consensus by 4.42 percent. The same report put the prior full-year EBITDA range at EUR 770 million to EUR 850 million, making the new outlook materially lower while excluding potential Sadara recovery measures.

What does the EBITDA miss mean?

The immediate issue is the gap between stable sales and weaker profitability. Solvay said the Sadara joint-venture framework includes mechanisms that could recover lost profitability, but those potential proceeds are excluded from the revised guidance. Cash generation is therefore the more useful investor test: the new free cash flow range is EUR 120 million to EUR 150 million, net of EUR 90 million of transformation expenses.

Beursduivel reported on October 19, 2026, that Jefferies maintained an Underperform rating and a EUR 20.00 price target. That target sits below the Lang & Schwarz price, while the company faces a plant interruption that has already affected EBITDA in both the second and third quarters.

Results arrive November 4

Solvay is scheduled to publish its complete third-quarter 2026 results on November 4, 2026, according to the company release. That publication should clarify the divisional contribution behind the EUR 1.03 billion of preliminary sales and whether the Sadara disruption has changed the cash outlook.

Stock reflects the revised outlook

The EUR 23.58 indication is EUR 1.32 below the Xetra close, a sharper move than the 4.42 percent EBITDA consensus miss because the outlook also reduces the range for full-year cash generation. The market is now weighing operational recovery against the timing of any contractual compensation.

The further course of trading is shown by the continuously updated real-time quote of Solvay stock.